Effects of prenatal perfluorooctane sulfonate (PFOS) exposure on lung maturation in the perinatal rat

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 74, Issue 5, 2005, Pages 405-416

  Grasty, R C ^a,b   Bjork, J A ^c   Wallace, K B ^c   Lau, C S ^a   Rogers, John M ^a,b,d  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Lung; Neonatal mortality; Perfluorooctane sulfonate; PFOS; Surfactant

Indexed keywords

DEXAMETHASONE; LUNG SURFACTANT; PERFLUOROOCTANE; PERFLUOROOCTANESULFONAMIDE; PERFLUOROOCTANESULFONYL FLUORIDE; PERLFUOROOCTANE SULFONATE; PHOSPHOLIPID; RETINOL PALMITATE; SURFACTANT; UNCLASSIFIED DRUG;

AMNION FLUID ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DYSPNEA; FETUS; FETUS LUNG MATURATION; GESTATIONAL AGE; HYDROLYSIS; LUNG ALVEOLUS CELL; LUNG ALVEOLUS WALL; LUNG PERFUSION; MASS SPECTROMETRY; NEWBORN MORTALITY; NONHUMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; TISSUE MICROARRAY;

ALKANESULFONIC ACIDS; ANIMALS; ANIMALS, NEWBORN; CELL DIFFERENTIATION; DEXAMETHASONE; FEMALE; FETAL ORGAN MATURITY; FLUOROCARBONS; GENE EXPRESSION PROFILING; LONGEVITY; MATERNAL EXPOSURE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOLIPIDS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PULMONARY ALVEOLI; PULMONARY SURFACTANTS; RATS; RATS, SPRAGUE-DAWLEY; VITAMIN A;

ANIMALIA; RODENTIA;

EID: 27644474700     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20059     Document Type: Article

References (66)

1. Ankley GT, Kuehl DW, Kahl MD, Jensen KM, Butterworth BC, Nichols JW. 2004. Partial life-cycle toxicity and bioconcentration modeling of perfluorooctanesulfonate in the northern leopard frog (Rana pipiens). Environ Toxicol Chem 23:2745-2755.
2. Austin ME, Kasturi BS, Barber M, Kannan K, MohanKumar PS, MohanKumar SM. 2003. Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ Health Perspect 111:1485-1489.
3. Batenburg JJ. 1992. Surfactant phospholipids: synthesis and storage. Am J Physiol 262:L367-385.
4. Burns J, Lundberg J, Olsen GW, Simpson CA, Mandel JH. 2002. Interim report No. 2, Determination of serum half-lives of several fluorochemicals. Report nr US EPA Docket AR-226-1086. St. Paul, MN: 3M Company.
5. Butenhoff JL, York R, Seacat A, Luebker D. 2002. Perfluorooctanesulfonate-induced perinatal mortality in rat pups is associated with a steep dose-response. Toxicologist 66:25.
6. Case MT, York RG, Christian MS. 2001. Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. Int J Toxicol 20:101-109.
7. Creuwels LA, van Golde LM, Haagsman HP. 1997. The pulmonary surfactant system: biochemical and clinical aspects. Lung 175:1-39.
8. DeLong CJ, Baker PR, Samuel M, Cui Z, Thomas MJ. 2001. Molecular species composition of rat liver phospholipids by ESI-MS/MS: the effect of chromatography J Lipid Res 42:1959-1968.
9. Dietl P, Haller T. 2005. Exocytosis of lung surfactant: from the secretory vesicle to the air-liquid interface. Annu Rev Physiol 67:595-621.
10. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. 2003. MAPPFinder: Using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 4:R7. Epub 2003 Jan 6.
11. Fraslon C, Bourbon JR. 1994. Retinoids control surfactant phospholipid biosynthesis in fetal rat lung. Am J Physiol 266:L705-L712.
12. Giesy JP, Kannan K. 2001. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol 35:1339-1342.
13. Grasty RC, Grey BE, Lau CS, Rogers JM. 2003. Prenatal window of susceptibility to perfluorooctane sulfonate-induced neonatal mortality in the Sprague-Dawley rat. Birth Defects Res Part B Dev Reprod Toxicol 68:465-471.
14. Guo Y, Martinez-Williams C, Yellowley CE, Donahue HJ, Rannels DE. 2001. Connexin expression by alveolar epithelial cells is regulated by extracellular matrix. Am J Physiol Lung Cell Mol Physiol 280: L191-L202.
15. Hallman M, Glumoff V, Ramet M. 2001. Surfactant in respiratory distress syndrome and lung injury. Comp Biochem Physiol A Mol Integr Physiol 129:287-294.
16. Hansen KJ, Clemen LA, Ellefson ME, Johnson HO. 2001. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ Sci Technol 35:766-770.
17. Harada K, Saito N, Inoue K, Yoshinaga T, Watanabe T, Sasaki S, Kamiyama S, Koizumi A. 2004. The influence of time, sex and geographic factors on levels of perfluorooctane sulfonate and perfluorooctanoate in human serum over the last 25 years. J Occup Health 46:141-147.
18. Hoff PT, Van de Vijver K, Van Dongen W, Esmans EL, Blust R, De Coen WM. 2003a. Perfluorooctane sulfonic acid in bib (Trisopterus luscus) and plaice (Pleuronectes platessa) from the Western Scheldt and the Belgian North Sea: distribution and biochemical effects. Environ Toxicol Chem 22:608-614.
19. Hoff PT, Van Dongen W, Esmans EL, Blust R, De Coen WM. 2003b. Evaluation of the toxicological effects of perfluorooctane sulfonic acid in the common carp (Cyprinus carpio). Aquat Toxicol 62:349-359.
20. Hu W, Jones PD, DeCoen W, King L, Fraker P, Newsted J, Giesy JP. 2003. Alterations in cell membrane properties caused by perfluorinated compounds. Comp Biochem Physiol C Toxicol Pharmacol 135:77-88.
21. Hu W, Jones PD, Upham BL, Trosko JE, Lau C, Giesy JP. 2002. Inhibition of gap junctional intercellular communication by perfluorinated compounds in rat liver and dolphin kidney epithelial cell lines in vitro and Sprague-Dawley rats in vivo. Toxicol Sci 68:429-436.
22. Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, Uno A, Saijo Y, Sata F, Yoshimura Y, Kishi R, Nakazawa H. 2004. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 112:1204-1207.
23. 14C]perfluorooctanesulfonate. Fundam Appl Toxicol 4:972-976.
24. Kannan K, Corsolini S, Falandysz J, Fillmann G, Kumar KS, Loganathan BG, Mohd MA, Olivero J, Van Wouwe N, Yang JH, Aldoust KM. 2004. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol 38:4489-4495.
25. Kannan K, Koistinen J, Beckmen K, Evans T, Gorzelany JF, Hansen KJ, Jones PD, Helle E, Nyman M, Giesy JP. 2001a. Accumulation of perfluorooctane sulfonate in marine mammals. Environ Sci Technol 35:1593-1598.
26. Kannan K, Newsted J, Halbrook RS, Giesy JP. 2002b. Perfluorooctanesulfonate and related fluorinated hydrocarbons in mink and river otters from the United States. Environ Sci Technol 36:2566-2571.
27. Kauffman SL. 1977. Acceleration of canalicular development in lungs of fetal mice exposed transplacentally to dexamethasone. Lab Invest 36:395-401.
28. Koval M. 2002. Sharing signals: connecting lung epithelial cells with gap junction channels. Am J Physiol Lung Cell Mol Physiol 283: L875-L893.
29. Kubwabo C, Vais N, Benoit FM. 2004. A pilot study on the determination of perfluorooctanesulfonate and other perfluorinated compounds in blood of Canadians. J Environ Monit 6:540-545.
30. Lau C, Butenhoff JL, Rogers JM. 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 198:231-241.
31. Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Stanton ME, Butenhoff JL, Stevenson LA. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II. Postnatal evaluation. Toxicol Sci 74:382-392.
32. Lee MD, King LS, Nielsen S, Agre P. 1997a. Genomic organization and developmental expression of aquaporin-5 in lung. Chest 111(Suppl):111S-113S.
33. Lee YC, Yellowley CE, Li Z, Donahue HJ, Rannels DE. 1997b. Expression of functional gap junctions in cultured pulmonary alveolar epithelial cells. Am J Physiol 272:L1105-L1114.
34. Losty PD, Pacheco BA, Manganaro TF, Donahoe PK, Jones RC, Schnitzer JJ. 1996. Prenatal hormonal therapy improves pulmonary morphology in rats with congenital diaphragmatic hernia. J Surg Res 65:42-52.
35. Martin JW, Mabury SA, Solomon KR, Muir DC. 2003. Bioconcentration and tissue distribution of perfluorinated acids in rainbow trout (Oncorhynchus mykiss). Environ Toxicol Chem 22:196-204.
36. Martin JW, Smithwick MM, Braune BM, Hoekstra PF, Muir DC, Mabury SA. 2004a. Identification of long-chain perfluorinated acids in biota from the Canadian Arctic. Environ Sci Technol 38:373-380.
37. Martin JW, Whittle DM, Muir DC, Mabury SA. 2004b. Perfluoroalkyl contaminants in a food web from Lake Ontario. Environ Sci Technol 38:5379-5385.
38. Massaro D, Massaro GD. 1986. Dexamethasone accelerates postnatal alveolar wall thinning and alters wall composition. Am J Physiol 251:R218-R224.
39. Massaro D, Massaro GD. 2001. Pulmonary alveolus formation: critical period, retinoid regulation and plasticity. Novartis Found Symp 234:229-241.
40. Massaro GD, Massaro D. 1992. Formation of alveoli in rats: postnatal effect of prenatal dexamethasone. Am J Physiol 263:L37-L41.
41. Massaro GD, Massaro D. 2000. Retinoic acid treatment partially rescues failed septation in rats and in mice. Am J Physiol Lung Cell Mol Physiol 278:L955-L960.
42. Mendelson CR. 2000. Role of transcription factors in fetal lung development and surfactant protein gene expression. Annu Rev Physiol 62:875-915.
43. Moulton PR. 2002. Principles and practices of unbiased stereology. An introduction for bioscientists. Baltimore, MD: The Johns Hopkins University Press. p 88-112.
44. Olsen GW, Burris JM, Mandel JH, Zobel LR. 1999. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J Occup Environ Med 41:799-806.
45. Olsen GW, Church TR, Larson EB, van Belle G, Lundberg JK, Hansen KJ, Burris JM, Mandel JH, Zobel LR. 2004. Serum concentrations of perfluorooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. Chemosphere 54:1599-1611.
46. Olsen GW, Huang H-Y, Helzlsouer KJ, Hansen KJ, Butenhoff JL, Mandel JH. 2005. Historical comparison of perfluorooctanesulfonate, perfluorooctanoate and other fluorochemicals in human blood. Environ Health Perspect 113:539-545.
47. Olsen GW, Church TR, Miller JP, Burris JM, Hansen KJ, Lundberg JK, Armitage JB, Herron RM, Medhdizadehkashi Z, Nobiletti JB, O'Neill EM, Mandel JH, Zobel LR. 2003a. Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ Health Perspect 111:1892-1901.
48. Olsen GW, Hansen KJ, Stevenson LA, Burris JM, Mandel JH. 2003b. Human donor liver and serum concentrations of perfluorooctane-sulfonate and other perfluorochemicals. Environ Sci Technol 37:888-891.
49. Olsen GW, Logan PW, Hansen KJ, Simpson CA, Burris JM, Burlew MM, Vorarath PP, Venkateswarlu P, Schumpert JC, Mandel JH. 2003c. An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site: biomonitoring. AIHA J (Fairfax, Va) 64:651-659.
50. Ramirez MI, Cao YX, Williams MC. 1999. 1.3 Kilobases of the lung type I cell T1α gene promoter mimics endogenous gene expression patterns during development but lacks sequences to enhance expression in perinatal and adult lung. Dev Dyn 215:319-331.
51. Rayani HH, Warshaw JB, Floros J. 1995. Dexamethasone enhances surfactant protein gene expression in streptozotocin-induced immature rat lungs. Pediatr Res 38:870-877.
52. Renner R. 2001. Growing concern over perfluorinated chemicals. Environ Sci Technol 35:154A-160A.
53. Robertson B, van Golde LM, Batenburg JJ. 1992. Pulmonary surfactant: from molecular biology to clinical practice. Amsterdam: Elsevier Science Publishers.
54. Rooney SA. 2001. Regulation of surfactant secretion. Comp Biochem Physiol A Mol Integr Physiol 129:233-243.
55. Rotenberg M, Gewolb IH. 1993. Reversal of lung maturational delay in the fetus of the diabetic rat using triiodothyronine or dexamethasone. Biol Neonate 64:318-324.
56. Scavo LM, Newman V, Ertsey R, Chapin CJ, Kitterman JA. 2003. Maternally administered dexamethasone transiently increases apoptosis in lungs of fetal rats. Exp Lung Res 29:211-226.
57. Seacat A, Thomford P, Hansen K, Clemen L, Eldridge S, Elcombe C, Butenhoff J. 2003. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183:117-131.
58. Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. 2002. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci 68:249-264.
59. Taniyasu S, Kannan K, Horii Y, Hanari N, Yamashita N. 2003. A survey of perfluorooctane sulfonate and related perfluorinated organic compounds in water, fish, birds, and humans from Japan. Environ Sci Technol 37:2634-2639.
60. Thebaud B, Barlier-Mur AM, Chailley-Heu B, Henrion-Caude A, Tibboel D, Dinh-Xuan AT, Bourbon JR. 2001. Restoring effects of vitamin A on surfactant synthesis in nitrofen-induced congenital diaphragmatic hernia in rats. Am J Respir Crit Care Med 164:1083-1089.
61. Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Barbee BD, Richards JH, Butenhoff JL, Stevens LA, Lau C. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I. Maternal and prenatal evaluations. Toxicol Sci 74:369-381.
62. Veness-Meehan KA, Bottone FGJ, Stiles AD. 2000. Effects of retinoic acid on airspace development and lung collagen in hyperoxia-exposed newborn rats. Pediatr Res 48:434-444.
63. Veness-Meehan KA, Pierce RA, Moats-Staats BM, Stiles AD. 2002. Retinoic acid attenuates O2-induced inhibition of lung septation. Am J Physiol Lung Cell Mol Physiol 283:L971-L980.
64. Williams MC. 1977. Development of the alveolar structure of the fetal rat in late gestation. Fed Proc 36:2653-2659.
65. Wrobel S. 2004. Bubbles, babies and biology: the story of surfactant. FASEB J 18:1624e.
66. Zoetis T, Hurtt ME. 2003. Species comparison of lung development. Birth Defects Res Part B Dev Reprod Toxicol 68:121-124.